Vitiligo – Epidemiology – Asia-Pacific
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years.
Clarivate Epidemiology’s vitiligo forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of vitiligo over the forecast period?
- Of all people diagnosed with vitiligo, how many cases are segmental versus non-segmental vitiligo?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following vitiligo subpopulations:
- Diagnosed prevalent cases of vitiligo.
- Diagnosed prevalent cases of vitiligo by subtype.
- Diagnosed prevalent cases of vitiligo by total body surface area.
Note: Coverage may vary by country.
Table of contents
- Vitiligo - Epidemiology - Asia-Pacific
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of vitiligo)
- Diagnosed prevalent cases of vitiligo
- Diagnosed prevalent cases of vitiligo by subtype
- Diagnosed prevalent cases of vitiligo by total body surface area
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.